Five decades
of peer-reviewed evidence.
GHK-Cu is not a new ingredient. It is one of the most extensively studied peptides in regenerative medicine — first isolated from human plasma in 1973 and continuously validated ever since. Here is what the science actually says.
The molecule
that rebuilds skin.
GHK (Glycyl-L-Histidyl-L-Lysine) is a naturally occurring tripeptide first isolated from human plasma by Pickart and Thaler in 1973. It has a high affinity for copper ions, forming the GHK-Cu complex that acts as a potent biological signal for tissue repair and regeneration.
GHK-Cu plasma levels decline dramatically with age — from approximately 200 ng/ml at age 20 to around 80 ng/ml by age 60. This decline correlates directly with the skin's decreasing capacity to repair itself and the visible onset of structural aging.
The peptide's amino acid sequence is present in the alpha 2(I) chain of type I collagen. When collagen is damaged, proteolytic enzymes release GHK into the site of injury — triggering the skin's own repair cascade. Topical application at 2% replicates this biological signal.
The hydration shield
from extremophile bacteria.
Ectoin is a naturally occurring stress-protection molecule produced by extremophilic bacteria to survive in extreme conditions — intense heat, desiccation, high salinity, and UV exposure. It has been studied for over 30 years for its ability to protect biological structures from environmental damage.
Its mechanism is unique: rather than sitting on the skin's surface as an occlusive barrier, Ectoin binds water molecules at a cellular level — forming a stable hydration complex that protects cell membranes, stabilises proteins, and reduces transepidermal water loss (TEWL) from within.
In the RHIVA formula, Ectoin serves a dual purpose — protecting the skin barrier during the GHK-Cu regeneration process, and reducing the potential for irritation that can accompany active ingredient delivery.
Penetration
is everything.
A peptide that stays on the skin's surface has no clinical effect. GHK-Cu must penetrate through the stratum corneum to reach the dermis where fibroblasts reside. Research confirms that GHK-Cu and its copper complexes are able to migrate through the membrane model of the stratum corneum — but only in the correct formulation environment.
The RHIVA microemulsion is an ultra-light, nanoscale oil-in-water carrier system designed to maximise transdermal delivery. It contains no silicones or occlusive agents that would form a surface barrier and reduce penetration. pH is calibrated to 6.5 — the range at which GHK-Cu has peak bioavailability and optimal copper binding.